Inlyta Archives -

Pfizer’s tyrosine kinase inhibitor Inlyta is already a cornerstone of treatment for some forms of cancer, but could

Could Pfizer’s Inlyta have a role in Alzheimer’s disease?

https://pharmaphorum.com/news/could-pfizers-inlyta-have-a-role-in-alzheimers-disease/

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the

Merck gets a leg-up for Keytruda in first-line kidney cancer

https://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/

The Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including

Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancer

https://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/

Merck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in

Keytruda combo cleared as first-line kidney cancer treatment in EU

https://pharmaphorum.com/news/keytruda-combo-cleared-first-line-kidney-cancer-treatment-eu/

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care

Keytruda combo set to become “standard of care” in kidney cancer

https://pharmaphorum.com/news/keytruda-combo-set-to-become-standard-of-care-kidney-cancer/

Inlyta